URO Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. (TSX VENTURE:URO) today announced that it has
obtained a CE Mark for the UroNIRS 2000(TM) Bladder Monitor System and will
officially launch the product in Europe with its distribution partner Medical
Measurement Systems B.V. (MMS) at the Annual EAU Conference in Stockholm Sweden
March 17 - 21, 2009.


The granting of the CE Mark will allow Urodynamix to expand distribution of its
UroNIRS products into the urology office and out-patient markets in Europe where
millions of men suffer from the symptoms of benign prostatic hyperplasia (BPH)
and require effective diagnosis prior to treatment. Urodynamix expects to
commence commercial shipments of UroNIRS 2000 to Europe in the first quarter of
2009.


"The receipt of the CE Mark sets the stage for our rollout of the UroNIRS
technology in Europe. We are very pleased to have achieved this major
milestone." said Barry Allen, President and CEO of Urodynamix. "The UroNIRS 2000
is a key part of our expansion from the acute care market into the larger office
based urology market and Europe is a major market to have access to. The UroNIRS
2000 is a user friendly and cost effective device for the urology office market
where we believe the non-invasive fast diagnostic procedure will have incredible
value."


"MMS is a market leader in urodynamics and we are looking forward to introducing
and promoting this exciting new technology," said Arjen J. de Weerd, President
of MMS. "By being able to provide Urodynamix's UroNIRS technology on a
stand-alone basis we will continue to provide the latest advances in
non-invasive diagnostic technology to our global customer base."


The UroNIRS 2000 is based on a wireless tablet PC with Urodynamix's proprietary
sensor configuration. It is compact, portable and specifically designed for ease
of use in the urologist's office setting. The UroNIRS 2000 utilizes a
non-invasive procedure to confirm the presence of bladder outlet obstruction in
men by identifying patients that have healthy bladder function yet suffer from
weak urinary stream, hesitancy, urinary retention and related symptoms. UroNIRS
2000 is safer, faster, less expensive and more comfortable than conventional
catheter-based diagnostics used to identify the same condition. Clinical studies
have shown that the UroNIRS 2000 device has an 86% success rate for accurately
identifying obstructed male patients, most of whom are good surgical candidates.


About Medical Measurement Systems B.V.

MMS has been producing urodynamic systems for more than 20 years, including
Solar SmartFlow(TM) Urodynamics Systems and Flowmaster(TM) UroFlow products. MMS
has an outstanding reputation for product development and innovation. Their
engineers, sales and marketing teams have daily contact with practicing nurses
and physicians all over the world, enabling MMS to develop diagnostic systems
that exactly meet the needs of today's healthcare professionals.


The main corporate office of MMS is located in Enschede, the Netherlands, where
all products are designed and tested to comply with American and European
medical safety regulations as well as international quality standards.

Global distribution takes place through branch offices in the United States,
Germany and The Netherlands and a worldwide network of highly qualified
distributors who sell and service MMS systems to university, public and private
hospitals in more than 60 countries.


About Urodynamix Technologies Ltd.

Urodynamix Technologies Ltd. is a Canadian medical device company developing and
commercializing non-invasive medical technology based on proprietary
applications of near-infrared spectroscopy (NIRS). The Company is currently
focused on products that aid in the diagnosis and treatment of urinary
incontinence, lower urinary tract symptoms, prostate cancer, benign prostatic
hyperplasia, and traumatic increases in intra-abdominal pressure that cause
abdominal compartment syndrome. Urodynamix's breakthrough medical technology has
the potential to beneficially affect more than 200 million people worldwide.


Certain information contained in this press release may be forward-looking and
is subject to unknown risks, which could cause actual results to differ
materially from those set forth or implied herein. Although the Company believes
that the expectations reflected in such forward-looking statements are
reasonable, it can give no assurance that such expectations will prove correct.

Urodynamix Technologies Ltd. (TSXV:URO)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024

Urodynamix Technologies Ltd. (TSXV:URO)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024